SCHEMBL6419799

SCHEMBL6419799

CC(C)(C)OC(=O)NNc1nc2nonc2nc1Nc1ccc(F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.48
TP53 P04637 6/20 0.48
MAPT P10636 4/20 0.48
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
RAB9A P51151 3/20 0.43
CDKN1A P38936 1/20 0.40
GAA P10253 3/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
NPC1 O15118 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
RECQL P46063 1/20 0.38
POLB P06746 1/20 0.38
ALDH1A1 P00352 1/20 0.37
GFER P55789 1/20 0.37
SYK P43405 1/20 0.36
NPR3 P17342 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
JAK2 O60674 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419677 0.88 GAA (0.49) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6414113 0.85 EGFR (0.49) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6416982 0.84 MAPT (0.45) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6416313 0.81 MAPT (0.47) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6416039 0.79 MEN1 (0.44) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6431994 0.77 GAA (0.46) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL3050610 0.77 SMN1; SMN2 (0.67) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL31606832 0.76 GAA (0.50) SMN1; SMN2MAPTMEN1KMT2ARAB9A
SCHEMBL6414172 0.75 GAA (0.40) MEN1KMT2ARAB9AGAALMNA
SCHEMBL6414257 0.74 GAA (0.39) MEN1KMT2ARAB9AGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 SMN1; SMN2 4369/4885TP53 4485/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.